Safety of cryoballoon ablation for the treatment of atrial fibrillation: First European results from the cryo AF Global Registry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F21%3A00009072" target="_blank" >RIV/00023884:_____/21:00009072 - isvavai.cz</a>

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/10.1111/pace.14237" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1111/pace.14237</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/pace.14237" target="_blank" >10.1111/pace.14237</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Safety of cryoballoon ablation for the treatment of atrial fibrillation: First European results from the cryo AF Global Registry

Popis výsledku v původním jazyce

Background Cryoballoon ablation for the treatment of patients with atrial fibrillation (AF) has been utilized in Europe for >15 years. Objectives Report patient and procedural characteristics that influence the safety of cryoablation for the treatment of AF. Methods Patients enrolled in the prospective, multicenter Cryo AF Global Registry were treated at 38 European centers. Freedom from a >= 30s episode of AF/atrial flutter (AFL)/atrial tachycardia (AT) at 12-months and serious complications were analyzed. Univariate and multivariable models identified baseline patient and procedural characteristics that predicted a procedure-related complication. Results Of the 1418 subjects who completed an index procedure, the cohort was 62 +/- 11 years of age, 37.7% female, and 72.2% paroxysmal AF (PAF). The mean procedure, left atrial dwell, and fluoroscopy times were 81 +/- 34, 54 +/- 25, and 14 +/- 13 min, respectively. Among the 766 patients with 12-month follow-up, freedom from a >= 30 s AF/AFL/AT recurrence was 83.3% (95% CI: 79.8%-86.3%) and 71.6% (95% CI: 64.6%-77.4%) in patients with PAF and persistent AF. The serious procedure- and device-related adverse event rates were 4.7% and 2.0%. No baseline patient characteristic independently predicted a procedure-related adverse event; however, prolonged procedure duration (OR = 1.01 [95% CI: 1.00-1.01]), use of general anesthesia (OR = 1.71 [95% CI: 1.01-2.92]), and delivery of a cavotricuspid isthmus line (OR = 3.04 [95% CI: 1.01-9.20]) were each independently associated with the occurrence of a serious procedural safety event (all p < .05).

Název v anglickém jazyce

Safety of cryoballoon ablation for the treatment of atrial fibrillation: First European results from the cryo AF Global Registry

Popis výsledku anglicky

Background Cryoballoon ablation for the treatment of patients with atrial fibrillation (AF) has been utilized in Europe for >15 years. Objectives Report patient and procedural characteristics that influence the safety of cryoablation for the treatment of AF. Methods Patients enrolled in the prospective, multicenter Cryo AF Global Registry were treated at 38 European centers. Freedom from a >= 30s episode of AF/atrial flutter (AFL)/atrial tachycardia (AT) at 12-months and serious complications were analyzed. Univariate and multivariable models identified baseline patient and procedural characteristics that predicted a procedure-related complication. Results Of the 1418 subjects who completed an index procedure, the cohort was 62 +/- 11 years of age, 37.7% female, and 72.2% paroxysmal AF (PAF). The mean procedure, left atrial dwell, and fluoroscopy times were 81 +/- 34, 54 +/- 25, and 14 +/- 13 min, respectively. Among the 766 patients with 12-month follow-up, freedom from a >= 30 s AF/AFL/AT recurrence was 83.3% (95% CI: 79.8%-86.3%) and 71.6% (95% CI: 64.6%-77.4%) in patients with PAF and persistent AF. The serious procedure- and device-related adverse event rates were 4.7% and 2.0%. No baseline patient characteristic independently predicted a procedure-related adverse event; however, prolonged procedure duration (OR = 1.01 [95% CI: 1.00-1.01]), use of general anesthesia (OR = 1.71 [95% CI: 1.01-2.92]), and delivery of a cavotricuspid isthmus line (OR = 3.04 [95% CI: 1.01-9.20]) were each independently associated with the occurrence of a serious procedural safety event (all p < .05).

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

PACE: Pacing and clinical electrophysiology

ISSN

0147-8389

e-ISSN

—

Svazek periodika

44

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

883-894

Kód UT WoS článku

000646716400001

EID výsledku v databázi Scopus

2-s2.0-85104521363